Stem cell differentiation and human liver disease

Citation for published version:

Digital Object Identifier (DOI):

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
World journal of gastroenterology : WJG

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Stem cell differentiation and human liver disease

Wen-Li Zhou, Claire N Medine, Liang Zhu, David C Hay

Wen-Li Zhou, Liang Zhu, Department of Gastroenterology, Changzheng Hospital, Second Military Medical University of China, Shanghai 200003, China
Wen-Li Zhou, Claire N Medine, David C Hay, Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, Scotland, United Kingdom

Author contributions: Zhou WL and Medine CN contributed towards the conception and design of the review; Zhu L contributed to supervision; Hay DC provided supervision and major input into manuscript preparation.

Supported by an RCUK fellowship, EP/E500145/1, to Hay DC; A grant from the Edinburgh Bioquarter, to Medine CN; China Scholarship Council, No.2010658022, to Zhou WL

Correspondence to: David C Hay, PhD, Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, Scotland, United Kingdom. davehay@talktalk.net

TelephoneNumber: +44-131-6519549 Fax: +44-131-6519501
Received: December 2, 2011 Revised: February 8, 2012
Accepted: February 26, 2012
Published online: May 7, 2012

Abstract

Human stem cells are scalable cell populations capable of cellular differentiation. This makes them a very attractive in vitro cellular resource and in theory provides unlimited amounts of primary cells. Such an approach has the potential to improve our understanding of human biology and treating disease. In the future it may be possible to deploy novel stem cell-based approaches to treat human liver diseases. In recent years, efficient hepatic differentiation from human stem cells has been achieved by several research groups including our own. In this review we provide an overview of the field and discuss the future potential and limitations of stem cell technology.

© 2012 Baishideng. All rights reserved.

Key words: Differentiation; Pluripotent stem cells; Hepatocyte-like cells; Liver development; Polymer chemistry; Regenerative medicine; Transplantation; Bio-artificial liver

INTRODUCTION

End stage liver disease (ESLD) is an irreversible condition that leads to the eventual failure of the liver. It may be the final stage of many liver diseases, for example, viral hepatitis, autoimmune hepatic disorders, fatty liver disease, drug induced liver injury, and hepatocellular carcinoma, with extremely poor prognosis. The incidence of ESLD is increasing worldwide[1] and current optimal treatment for ESLD is orthotopic liver transplantation[2]. However limited availability of donor livers and immunological incompatibilities are two major obstacles to its routine deployment[3]. This highlights the important need for alternative therapeutic strategies. Researchers have proposed that stem cell biology could provide a scalable answer for the treatment of ESLD, providing cells for transplant and/or cell sources for studying liver disorders and identifying novel treatments.

Cell-based therapy requires the use of cells to replace or facilitate the repair of damaged tissue. Candidate cells for this approach include bipotential, multipotent, pluripotent cells, and primary hepatocytes. Pluripotent stem cells (PSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), possess the ability to self renew and differentiate into all somatic cells, offering unlimited potential and are not restricted by donor tissue supply.

hESCs are derived from the inner cell mass of the human blastocyst, and can differentiate into all three primary germ layers[30]. Human iPSCs are produced by forced
expression of specific stem cell genes\(^5\). In recent years, researchers have developed robust procedures to generate functional hepatocyte-like cells (HLCs) from both PSC populations\(^6\)\(^-\)\(^8\). However, it is notable that PSC strategies have not yielded, as yet, a cell type that appropriately contributes to tissue homeostasis as cell transplantation frequently results in tumour formation\(^9\)\(^-\)\(^10\). As a result, scalable cell-based therapies from PSCs are likely to be long-term strategies which require significant refinement.

Extra-corporeal support has been proposed as a medium strategy, in particular bio-artificial livers, to treat human liver disease. Bio-artificial livers (BALs) are designed to filter and biotransform toxic substances, and have been used successfully to bridge patients to transplant or treat acute liver failure. Research demonstrates that BALs can reduce mortality in acute liver failure compared with traditional standard medical therapy\(^11\)\(^,\)\(^12\), but the application has been severely limited by the poor availability of functional human hepatocytes. By employing PSC technology, it may now be possible to produce humanised BAL devices at reasonable cost.

In addition to their important role in the clinic, human hepatocytes have a critical part to play in the drug discovery process. Many candidate compounds fail at late stage or even after approval due to unanticipated toxicity. In routine drug discovery, the pharmaceutical industry deploys the tumor-derived cells and primary hepatocytes to screen compounds. While these models are useful, they do not always extrapolate to human biology and exhibit poor lifespan and variable metabolic activity. PSCs-derived hepatocytes have the potential to overcome these problems. Advances in stem cell biology and reprogramming have allowed the development of novel models which have the potential to provide another level of understanding behind the pathophysiology of liver diseases. iPSC modelling also provides us with potential system to better understand the influence of gene polymorphisms.

Human PSCs derived HLCs show great promise for research and clinical applications including cell-based therapies, drug development, and disease modeling. This review gives an overview of human hepatic differentiation from PSCs and their potential application in modern medicine.

**CURRENT CELL SOURCES USED IN HEPATOLOGY**

**Primary human hepatocytes and liver cancer cell lines**

Hepatocytes are the principle cell type found in the liver and perform the majority of the liver functions. Primary human hepatocytes (PHHs) are therefore a useful tool for medical applications such as cell-based therapy and drug discovery. However, PHHs are mainly obtained from scarce and low quality resected surgical specimens\(^13\). The scarcity and variability in these preparations restricts their widespread application in vivo\(^14\). Therefore liver cell lines have been employed routinely as they demonstrate long lifespan and are easy to maintain. HepG2 is a liver cell line derived from fetal tissue which exhibits poor metabolic function and secrete a variety of soluble serum proteins\(^15\). They have been used as a model system for cytochrome P450 (CYP) metabolism and toxicity. And additionally they have been used in clinical trials with bioartificial liver devices\(^16\)\(^-\)\(^17\). Interestingly, a clonal derivative of the HepG2 line, C3A, demonstrates marked reduction in α-fetoprotein (AFP) and increased albumin (ALB) secretion, indicating a more mature status in vivo. More recently, a new human hepatoma cell line has been derived. HepaRG demonstrates a number of liver-specific functions including the expression of CYP 1A2, 2B6, 2C9, 2E1, 3A4\(^18\)\(^-\)\(^19\) and better overall performance than existing liver cell lines. Although informative and scalable, liver cancer cell lines show lower drug-metabolizing activity than their adult counterparts and do not accurately predict human drug toxicity \(^20\) and therefore do not constitute a real alternative to the gold standard primary hepatocyte. Moreover, such cells may provide interesting in vitro models or the bio-component of the BAL, but they could not be used for cell transplantation in vivo.

**Oval cells and hepatoblasts**

Oval cells are an adult liver cell population that emerges from the biliary tree following chronic liver injury. Several studies have investigated the transplantation of oval cells showing that these bipotential cells could proliferate and contribute to both parenchyma and biliary epithelia in vivo\(^21\)\(^-\)\(^28\). Oval cells express the stem cell markers Thy-1 (CD90), CD34 and Sca-1, along with liver-specific markers, including AFP, Gamma-glutamyltransferase, laminin and cytokeratin 19 (CK 19)\(^23\)\(^,\)\(^24\).

The tissue microenvironment plays an essential role in orchestrating oval cell-mediated liver regeneration. Laminin contributes to the maintenance of undifferentiated progenitor cells and progenitor cell-mediated tissue repair\(^29\). Moreover, Kallis et al\(^29\) demonstrated that extracellular matrix (ECM) remodelling during resolution and laminin deposition was likely to be important prerequisite to hepatic progenitor cell activation, expansion and repair.

Similar to oval cells, hepatoblasts from fetal liver could also represent a potential source of hepatocytes and biliary epithelial cells\(^24\)\(^,\)\(^31\). The bipotential nature of this cell type also makes it an attractive target for therapy. Transplant studies demonstrate that hepatoblasts may be a potential therapeutic strategy for ESLDs or hepatic failure. Although great progress in the fundamental research and clinical application have been made, there are still limitations to widespread use of these cells, such as low cell number in vivo, no specific biomarker for purification and poor expansion in vitro.

**Bone marrow stem cells and mesenchymal stem cell**

The bone marrow (BM) contains stem cells populations in vivo. They can be roughly divided into of hematopoietic (HSCs) and nonhematopoietic stem cells usually referred...
HEPATIC DIFFERENTIATION FROM PLURIPOTENT STEM CELLS

Human ESCs are derived from the inner cell mass of blastocyst stage embryos and are highly primitive cells which exhibit pluripotency and the ability to self-renew. Rambhatla et al. reported the directed differentiation of human ESCs to HLCs for the first time in 2003, which could express some hepatocyte markers. Since then labs have established more robust and efficient procedures to derive better functioning HLCs. Embryoid body (EB) formation has been one method to differentiate ESCs into hepatocytes. However, this approach exhibits limitations to scale and culture definition. Therefore, monolayer adherent culture systems have been developed to direct ESC hepatic differentiation depending on surrounding microenvironment. The role of MSCs in liver regeneration and disease has been evidenced in animal models. Moreover, MSC based therapies for patients with ESLDs have shown promise in phase I and II clinical trials. Treatment was well tolerated by all patients with liver fibrosis and hepatic function improved following MSCs transplantation and during the follow-up. Peng et al. reported that the biochemical hepatic index and MELD score were markedly improved from 2-3 wk post transplantation. However, long-term hepatic function were not significantly enhanced in 527 patients with liver failure caused by hepatitis B. Although MSC transplantation confers benefit to patients with liver cirrhosis, it may not be applicable to all kind of ESLDs.

HEPATIC DIFFERENTIATION IN CELL-BASED THERAPIES AND TOOLS

Hepatic differentiation for cell-based therapy

PSCs offer a possible source to treat liver disease. Cell therapy for liver disease includes transplantation (including genome edited cells to correct metabolic defects) and bio-artificial liver devices. The cell-based approaches are very encouraging, but further studies are required to demonstrate long-term safety of cell-based transplantation.

In the interim BALs containing hepatocytes could provide alternative support for patients with acute hepatic failure or awaiting liver transplantation. Efforts to generate long-lived functional HLCs may allow the development of more highly effective BALs. The potential application of human stem cells in cell-based therapy for liver diseases is summarised in Figure 1.
have provided models that may overcome some of the problems associated with existing technology. Moreover, in parallel with extracorporeal device development, stem-cell-derived HLCs in three dimensional (3D) are more likely to mimic human liver properties in vitro.

**Hepatic differentiation for disease modelling**

PSCs have provided scientists with novel models to study human liver disease. Rashid *et al.*[60] reported an effective procedure for hepatocyte generation from iPSCs exhibiting disease mutations. Using these cells, they modeled inherited metabolic disorders that affect the liver; alpha1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease type 1a. These models accurately reflected elements of the disease process. More recently research iPSCs, obtained from patients with tyrosinemia, glycogen storage disease, progressive familial hereditary cholestasis, and Crigler-Najjar syndrome, were differentiated into functioning HLCs[68]. These inherited liver diseases that mainly arise as a result of loss of function mutation, therefore these studies offers a unique opportunity to study the effects of specific gene defects on human liver biology and to better understand liver pathogenesis in disease.

**Improving hepatic differentiation**

PSC technologies have the potential to produce unlimited amounts of human liver cells. As discussed above, human hepatocytes from PSCs could be utilized for cell-based therapy, assessment of drug toxicity and disease modelling. Therefore, the PSC-derived HLCs should be reliable, stable in character and display high levels of metabolic activity. A better understanding of human liver development and optimal tissue microenvironments are likely to play an important role in this process.

**HUMAN LIVER DEVELOPMENT**

Liver development occurs through a series of reciprocal tissue interactions between the embryonic endoderm and...
nearby mesoderm. Endoderm contributes to the digestive
tract and has a principal role in the development of the
liver (Figure 3). The secretions of fibroblast growth factor
(FGF) and bone morphogenetic protein (BMP) from the
cardiac mesoderm and septum transversum mesenchyme
(STM) help orchestrate human liver development from
foregut endoderm in concert\[6,70,71\]. Three to 4 wk post fertilisation
cells called hepatoblasts, positive for CK19 and HepPar1, are detected for
the first time\[31\]. The hepatoblasts proliferate and form the
liver bud. The hepatic endoderm thickens into a columnar
epithelium, and hepatoblasts delaminate and invade the
STM and undergo cellular proliferation and differen-
tiation\[72,73\]. Between 6-8 wk gestation, the bile duct and
hepatic structure are easily identified\[31\]. Maturation of
hepatocytes and bile epithelial cells continues after birth.
An overview of embryonic liver development is summa-
rized in Figure 3.

### IMPROVING CELL CULTURE

**MICROENVIRONMENT**

The tissue microenvironment also plays an essential role
in liver development and hepatic differentiation. Two
dimensional (2D) hepatic differentiation is probably
the most widely used system in laboratories. While this
technology is efficient and scalable, there are several
drawbacks related to 2D culture, including poor drug inducibility
and rapid cell dedifferentiation. During human
liver development, hepatocytes mature in a 3D envi-
ronment with a number of cell types providing support.
In light of the increasing need for better-differentiated hepatocytes from PSCs, we and others have developed 3D systems to improve and stabilize hepatocyte-cell phenotype(s).

Undoubtedly 3D culture leads to improvements in hepatic function. In the future modulation of oxygenation and physiological delivery of nutrients in 3D environment have great potential to improve cell phenotype and therefore utility.

**CONCLUSION**

The development of hESCs and iPSC technology has led to a new era of discovery in liver medicine. Advances in PSC technology offer the promise of scalable human hepatocytes for cell-based therapies, assessment of drug efficacy and toxicity, and disease modelling. The challenge remains to cost effectively scale up this technology for industrial manufacture. A better knowledge of liver development and the use of novel supportive culture systems will help to improve the manner in which we derive mature human hepatocytes.

**REFERENCES**

2. Miró JM, Laguno M, Moreno A, Rimola A. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 2006; 44: S140-S145
20. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 2003; 31: 1035-1042


39 Payne C, King J, Hay D. The role of activin/nodal and Wnt signaling in endoderm formation. Vitam Horm 2011; 85: 207-216


41 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell 2006; 126: 663-676


45 Liu H, Kim Y, Bharadwaj S, Marchionna L, Jang YV. In vivo liver regeneration potential of human induced pluripotent stem


Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. *Hepatology* 2010; 51: 297-305


Duncan SA, Watt AJ. BMPs on the road to hepatogenesis. *Genes Dev* 2001; 15: 1879-1884

McLin VA, Rankin SA, Zorn AM. Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver and pancreas development. *Development* 2007; 134: 2207-2217


Zhao R, Duncan SA. Embryonic development of the liver. *Hepatology* 2005; 41: 956-967

Tanimizu N, Miyajima A. Molecular mechanism of liver development and regeneration. *Int Rev Cyto* 2007; 259: 1-48

